Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

505 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease.
Buckles VD, Xiong C, Bateman RJ, Hassenstab J, Allegri R, Berman SB, Chhatwal JP, Danek A, Fagan AM, Ghetti B, Goate A, Graff-Radford N, Jucker M, Levin J, Marcus DS, Masters CL, McCue L, McDade E, Mori H, Moulder KL, Noble JM, Paumier K, Preische O, Ringman JM, Fox NC, Salloway S, Schofield PR, Martins R, Vöglein J, Morris JC; Dominantly Inherited Alzheimer's Network. Buckles VD, et al. Among authors: salloway s. Alzheimers Dement. 2022 Oct;18(10):1754-1764. doi: 10.1002/alz.12505. Epub 2021 Dec 2. Alzheimers Dement. 2022. PMID: 34854530 Free PMC article.
Disease-modifying therapies in Alzheimer's disease.
Salloway S, Mintzer J, Weiner MF, Cummings JL. Salloway S, et al. Alzheimers Dement. 2008 Mar;4(2):65-79. doi: 10.1016/j.jalz.2007.10.001. Epub 2008 Feb 20. Alzheimers Dement. 2008. PMID: 18631951 Review.
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators. Salloway S, et al. Neurology. 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18. Neurology. 2009. PMID: 19923550 Free PMC article. Clinical Trial.
Subregional neuroanatomical change as a biomarker for Alzheimer's disease.
Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM; Alzheimer's Disease Neuroimaging Initiative. Holland D, et al. Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20954-9. doi: 10.1073/pnas.0906053106. Proc Natl Acad Sci U S A. 2009. PMID: 19996185 Free PMC article.
Longitudinal change of biomarkers in cognitive decline.
Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Lo RY, et al. Arch Neurol. 2011 Oct;68(10):1257-66. doi: 10.1001/archneurol.2011.123. Epub 2011 Jun 13. Arch Neurol. 2011. PMID: 21670386 Free PMC article.
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease.
Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, Minthon L, Trojanowski JQ, Shaw LM, Faluyi YO, Vellas B, Dubois B, Blennow K, Buerger K, Teipel SJ, Weiner M, Hampel H; Alzheimer's Disease Neuroimaging Initiative. Ewers M, et al. Neurobiol Aging. 2012 Aug;33(8):1599-608. doi: 10.1016/j.neurobiolaging.2011.05.005. Epub 2011 Jun 17. Neurobiol Aging. 2012. PMID: 21684041 Free PMC article.
505 results